Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-696P is a pseudogene derived from the U6 small nuclear RNA gene family. U6 snRNA is an essential and highly conserved non-coding RNA in eukaryotes, serving as a crucial catalytic component of the spliceosome responsible for splicing pre-mRNA. Vertebrate genomes often contain many U6-derived pseudogenes; these are DNA sequences with high similarity to functional U6 snRNA genes, but lack the regulatory or coding capacity to generate a functional snRNA molecule[3][1]. RNU6-696P does not produce a functional RNA or protein, shows no direct biological activity, and is not classified as a therapeutic target. Some studies report altered expression of RNU6-696P in diseases such as nasopharyngeal carcinoma, but its role appears to be limited to that of a marker rather than a functional contributor to cellular processes[2]. Key Points: - Not a protein, receptor, enzyme, or transporter. - Lacks direct function; derivative of a gene crucial in pre-mRNA splicing (the functional U6 snRNA, which is not the same as the pseudogene). - Not a therapeutic target; not druggable; no known drugs interact with it. - Downregulation may be detected in certain cancers but not as a mechanistic driver[2]. - Should not be used as a synonym for functional U6 snRNA or its complex. Summary: RNU6-696P is a pseudogene of U6 small nuclear RNA, not a functional molecule, protein, or actionable drug target. It is most relevant as an expression marker in specific research settings and should not be confused with canonical U6 snRNA, a molecule essential for spliceosomal function[2][3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 696, pseudogene (RNU6-696P).